<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771224</url>
  </required_header>
  <id_info>
    <org_study_id>REF453</org_study_id>
    <nct_id>NCT01771224</nct_id>
  </id_info>
  <brief_title>Effect of FAn-7 in UC Activity</brief_title>
  <acronym>FAUC</acronym>
  <official_title>Effect of Palmitoleic Acid (FAn-7) on Expression of HNF4γ and Ulcerative Colitis (UC) Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Inflammatory bowel disease (IBD) refers to two chronic diseases that cause
      intestinal inflammation, ulcerative colitis (UC) and Crohn's disease (CD). The conventional
      treatment is not effective; therefore, alternative therapies may be effective specially in UC
      patients. Fatty acid (FA) may have a beneficial effect on some UC patients. The increasing
      incidence and prevalence of UC and ineffective treatments in some patients, allows search
      coadjuvant therapies. Objective: Quantification of differences between patients with and
      without FA. Methods: In two groups of patients with UC is administered FA and placebo. We
      will measure the changes clinical, endoscopic and histological in both groups, before and
      after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical and endoscopic remission</measure>
    <time_frame>2 months</time_frame>
    <description>We will perfom a basal and final colonoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantification IL-6 in colonic mucosa</measure>
    <time_frame>2 months</time_frame>
    <description>quantification of IL-6 by RT-PCR in colonic mucosa at before and after the intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>palmitoleic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palmitoleic acid: 720 mg/day for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill: 720 mg/day for 56 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Palmitoleic acid</intervention_name>
    <description>Palmitoleic acid and 5-ASA</description>
    <arm_group_label>palmitoleic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a histopathologically confirmed diagnosis of UC.

          -  With mild and moderate disease.

          -  Patients treated with only doses of 5-aminosalicylates (5-ASA)

          -  BMI, 18 to 34.9 kg/m2

          -  Born in Mexico the last two generations

          -  Each patient will be asked to sign and date the consent form, to indicate that you
             agree to participate.

        Exclusion Criteria:

          -  Patient with associated diseases such as diabetes mellitus, hypertension,
             dyslipidemia, atherosclerosis and malabsorption syndrome.

          -  With autoimmune diseases (lupus, HIV, cancer and hepatitis), colitis (infectious,
             post-radiation, post-drug, indeterminate) and Crohn's Disease.

          -  If the patient use drugs that inhibit fat absorption.

          -  Patients after partial or total resection of stomach or small intestine.

          -  Steroid users.

          -  Patients in remission histology, clinical and endoscopic.

          -  Patients treated with FAn-3,6 or 9.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús K Yamamoto, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inflammatory Bowel Disease Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nallely Bueno, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inflammatory Bowel Disease Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesus K Yamamoto, MD, PhD</last_name>
    <phone>54870900</phone>
    <phone_ext>2710</phone_ext>
    <email>kazuofurusho@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nallely Bueno, MSc</last_name>
    <phone>54870900</phone>
    <phone_ext>2712</phone_ext>
    <email>nallely_bh5@yahoo.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>INCMNSZ</name>
      <address>
        <city>DF</city>
        <state>Tlalpan</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus K Furusho, MD, PhD</last_name>
      <phone>+5554870900</phone>
      <phone_ext>2710</phone_ext>
      <email>kazuofurusho@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nallely Bueno, MSc</last_name>
      <phone>+5554870900</phone>
      <phone_ext>2712</phone_ext>
      <email>nallely_bh5@yahoo.com.mx</email>
    </contact_backup>
    <investigator>
      <last_name>Jesus K Yamamoto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nallely Bueno, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Bueno-Hernández N, Sánchez-Muñoz F, Barreto-Zuñiga R, Dominguez-López A, Yamamoto-Furusho JK. Expression of HNF4γ is downregulated in patients with active ulcerative colitis (UC) compared to UC patients in remission and healthy controls. Inflamm Bowel Dis. 2011 Aug;17(8):E91. doi: 10.1002/ibd.21753. Epub 2011 May 25.</citation>
    <PMID>21618351</PMID>
  </results_reference>
  <results_reference>
    <citation>Drewes T, Senkel S, Holewa B, Ryffel GU. Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Mol Cell Biol. 1996 Mar;16(3):925-31.</citation>
    <PMID>8622695</PMID>
  </results_reference>
  <results_reference>
    <citation>Gruber L, Lichti P, Rath E, Haller D. Nutrigenomics and nutrigenetics in inflammatory bowel diseases. J Clin Gastroenterol. 2012 Oct;46(9):735-47. doi: 10.1097/MCG.0b013e31825ca21a. Review.</citation>
    <PMID>22941427</PMID>
  </results_reference>
  <results_reference>
    <citation>Daigo K, Kawamura T, Ohta Y, Ohashi R, Katayose S, Tanaka T, Aburatani H, Naito M, Kodama T, Ihara S, Hamakubo T. Proteomic analysis of native hepatocyte nuclear factor-4α (HNF4α) isoforms, phosphorylation status, and interactive cofactors. J Biol Chem. 2011 Jan 7;286(1):674-86. doi: 10.1074/jbc.M110.154732. Epub 2010 Nov 3. Erratum in: J Biol Chem. 2013 Aug 16;288(33):24161.</citation>
    <PMID>21047794</PMID>
  </results_reference>
  <results_reference>
    <citation>Nieto N, Torres MI, Ríos A, Gil A. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr. 2002 Jan;132(1):11-9.</citation>
    <PMID>11773501</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishida T, Miwa H, Shigematsu A, Yamamoto M, Iida M, Fujishima M. Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut. 1987 Aug;28(8):1002-7.</citation>
    <PMID>3117625</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, Lambert G, Kurotani R, Nagashima K, Gonzalez FJ, Inoue Y. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis. 2008 Jul;14(7):908-20. doi: 10.1002/ibd.20413.</citation>
    <PMID>18338782</PMID>
  </results_reference>
  <results_reference>
    <citation>Taraviras S, Mantamadiotis T, Dong-Si T, Mincheva A, Lichter P, Drewes T, Ryffel GU, Monaghan AP, Schütz G. Primary structure, chromosomal mapping, expression and transcriptional activity of murine hepatocyte nuclear factor 4gamma. Biochim Biophys Acta. 2000 Jan 31;1490(1-2):21-32.</citation>
    <PMID>10786614</PMID>
  </results_reference>
  <results_reference>
    <citation>Watanabe T, Kobunai T, Toda E, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Yamamoto Y, Hata K, Kojima T, Yokoyama T, Konishi T, Okayama Y, Sugimoto Y, Oka T, Sasaki S, Ajioka Y, Muto T, Nagawa H. Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):415-20.</citation>
    <PMID>17255260</PMID>
  </results_reference>
  <results_reference>
    <citation>Wille JJ, Kydonieus A. Palmitoleic acid isomer (C16:1delta6) in human skin sebum is effective against gram-positive bacteria. Skin Pharmacol Appl Skin Physiol. 2003 May-Jun;16(3):176-87.</citation>
    <PMID>12677098</PMID>
  </results_reference>
  <results_reference>
    <citation>Wisely GB, Miller AB, Davis RG, Thornquest AD Jr, Johnson R, Spitzer T, Sefler A, Shearer B, Moore JT, Miller AB, Willson TM, Williams SP. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure. 2002 Sep;10(9):1225-34.</citation>
    <PMID>12220494</PMID>
  </results_reference>
  <results_reference>
    <citation>Okuma Y, Shirao T, Sakamoto A. [Constipation in intracranial diseases--correlation betweeen the cerebrospinal fluid pressure and constipation]. Saishin Igaku. 1971 Jan;26(1):139-44. Japanese.</citation>
    <PMID>5539258</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu F, Dassopoulos T, Cope L, Maitra A, Brant SR, Harris ML, Bayless TM, Parmigiani G, Chakravarti S. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007 Jul;13(7):807-21.</citation>
    <PMID>17262812</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Jesús Kazuo Yamamoto Furusho</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Palmitoleic acid ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

